Journal ArticleDOI
Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder
Mehdi Ghasemi,Mohammad Hossein Kazemi,Mohammad Hossein Kazemi,Abolghasem Yoosefi,Abbas Ghasemi,Pedram Paragomi,Homayoun Amini,Mohammad H. Afzali,Mohammad H. Afzali +8 more
TLDR
It was shown that ketamine is as effective as ECT in improving depressive symptoms in MDD patients and have more rapid antidepressant effects compared with the ECT.Abstract:
Accumulating evidence suggests that N-methyl-d-aspartate receptor (NMDAR) antagonists (e.g. ketamine) may exert rapid antidepressant effects in MDD patients. In the present study, we evaluated the rapid antidepressant effects of ketamine compared with the electroconvulsive therapy (ECT) in hospitalized patients with MDD. In this blind, randomized study, 18 patients with DSM-IV MDD were divided into two groups which received either three intravenous infusions of ketamine hydrochloride (0.5 mg/kg over 45 min) or ECT on 3 test days (every 48 h). The primary outcome measure was the Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS), which was used to rate overall depressive symptoms at baseline, 24 h after each treatment, 72 h and one week after the last (third) ketamine or ECT. Within 24 h, depressive symptoms significantly improved in subjects receiving the first dose of ketamine compared with ECT group. Compared to baseline level, this improvement remained significant throughout the study. Depressive symptoms after the second dose ketamine was also lower than the second ECT. This study showed that ketamine is as effective as ECT in improving depressive symptoms in MDD patients and have more rapid antidepressant effects compared with the ECT.read more
Citations
More filters
Journal ArticleDOI
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Gerard Sanacora,Mark A. Frye,William M. McDonald,Sanjay J. Mathew,Sanjay J. Mathew,Mason S. Turner,Alan F. Schatzberg,Paul Summergrad,Charles B. Nemeroff +8 more
TL;DR: Information is provided on potentially important issues related to the off-label treatment approach of ketamine that should be considered to help ensure patient safety and the limitations of the available data.
Journal ArticleDOI
A brief history of the development of antidepressant drugs: from monoamines to glutamate.
TL;DR: The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a number of clinical studies, has shown the most promise as a novel glutamatergic-based treatment for MDD.
Journal ArticleDOI
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
Alexander McGirr,Marcelo T. Berlim,David J. Bond,Marcelo Pio de Almeida Fleck,Lakshmi N. Yatham,Raymond W. Lam +5 more
TL;DR: It is suggested that single administrations ketamine are efficacious in the rapid treatment of unipolar and bipolar depression and the potential efficacy of other glutamatergic agents.
Journal ArticleDOI
Side-effects associated with ketamine use in depression: a systematic review
Brooke Short,Brooke Short,Joanna Fong,Verònica Gálvez,Verònica Gálvez,William Shelker,Colleen Loo +6 more
TL;DR: This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses and suggests a selective reporting bias with limited assessment of long-term use and safety and after repeated dosing.
Journal ArticleDOI
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Guillaume Fond,Anderson Loundou,Corentin Rabu,Alexandra Macgregor,Christophe Lançon,Marie Brittner,Jean-Arthur Micoulaud-Franchi,Raphaëlle Richieri,Philippe Courtet,Mocrane Abbar,Matthieu Roger,Marion Leboyer,Laurent Boyer +12 more
TL;DR: The present meta-analysis confirms ketamine’s efficacy in depressive disorders in non-ECT studies, as well as in ECT studies, and further studies are warranted to detail efficacy in bipolar disorders and other specific depressed populations.
References
More filters
Journal ArticleDOI
A rating scale for depression
TL;DR: The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information.
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.